Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD

S. Pezzotta, C. Del Fante, L. Scudeller, G. C. Rossi, C. Perotti, P. E. Bianchi, E. Antoniazzi

Research output: Contribution to journalArticlepeer-review


Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2-3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5-72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P
Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalBone Marrow Transplantation
Issue number1
Publication statusPublished - Jan 1 2017


  • Adult
  • Blood Platelets/chemistry
  • Dry Eye Syndromes/drug therapy
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease/drug therapy
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions/administration & dosage/adverse effects/chemistry
  • Prospective Studies
  • Quality of Life


Dive into the research topics of 'Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD'. Together they form a unique fingerprint.

Cite this